Study suggests aspirin may help lower risk of death from severe COVID-19 complications
Scientists stated that aspirin can reduce the production of immune cells in patients with pre-existing cardiovascular disease, thus helping in reducing the incidence of a cytokine storm
COVID-19 infection affects different people differently; while some people do not present with any symptoms, others may experience severe complications such as acute respiratory distress syndrome (ARDS), pneumonia, septic shock, abnormal blood clotting and multiple organ failure, among others. Abnormal coagulation of blood can allow these blood clots to get lodged into the lungs, brain or heart, resulting in severe consequences and even death.
Doctors have been using various medications such as blood thinners and tissue plasminogen activator to resolve the blood clots. However, these medications may have some side effects.
Recently, researchers from the University of Maryland School of Medicine have stated that the intake of aspirin, a well-known drug with a satisfactory safety profile, can help reduce the risk of death in people admitted to the hospital with COVID-19 infection.
The effect of aspirin
In the recent study published in the journal Anesthesia & Analgesia on 21 October 2020, scientists collected the data of 412 patients, with an average age of 55 years, who were hospitalised at the University of Maryland Medical Center in Baltimore and three other hospitals along the East Coast in the United States between March 2020 and July 2020.
One-fourth of these patients had taken daily low-dose aspirin (around 81 milligrammes) to manage their cardiovascular disease either seven days prior to their admission or within the 24 hours after their admission to the hospital. This means that out of 412 patients, 314 patients did not receive aspirin, while 98 patients were given low doses of aspirin.
Reduced risk of death
Before analysing the results, the scientists took several factors such as age, gender, and body mass index into account. The researchers also included pre-existing conditions such as hypertension, diabetes, heart disease, kidney disease and liver disease.
The results of the study showed that:
- The risk of requiring mechanical ventilation for breathing difficulty was 35.7 percent in patients who took aspirin while it was 48.4 percent in non-aspirin patients.
- The risk of getting admitted to intensive care units (ICUs) was 38.8 percent in patients who took aspirin while it was 51.0 percent in non-aspirin patients.
Surprisingly, the results further showed that the intake of aspirin was associated with a 47 percent less risk of in-hospital death as compared to those who were not taking aspirin.
Preventing severe COVID-19 complications
With this study, scientists concluded that this inexpensive, accessible medication can help in preventing severe complications. Aspirin has anti-inflammatory properties, which may have protective effects on the lungs during COVID-19 infection.
Scientists stated that aspirin can reduce the production of immune cells such as interleukin-6 (IL-6), C-reactive protein (CRP), and macrophages in patients with pre-existing cardiovascular disease. This can help in reducing the incidence of a cytokine storm.
However, further research is needed to confirm the relationship between the use of aspirin and its effect on lung injury and deaths related to COVID-19 infection.
For more information, read our article on Aspirin.
Health articles in Firstpost are written by myUpchar.com, India’s first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.
The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor firstpost is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.
Antibody development and neutralisation of the virus have been suggested to be some of the deciding factors that predict the outcomes of COVID-19. As a result, several studies have been conducted in the past few months to determine whether humans produce a robust immune response against SARS-CoV-2, the causative agent of novel coronavirus disease.
WHO advises against use of Remdesivir to treat COVID-19, says drug has no 'important effect' to reduce deaths
A WHO Guideline Development Group of international experts said there was 'no evidence based on currently available data that the anti-viral drug does improve patient-important outcomes'
Flavanols in cocoa improve brain vascular function, cognition in young, healthy adults, says new study
Flavanols are polyphenols belonging to a class of phytonutrients called flavonoids. This phytonutrient has antioxidant potential and so is considered highly beneficial.